Clinical Trial Update: A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids) [Phase 3]

View source ↗

Summary

A Phase 3 pharmacokinetics and safety study of dupilumab in children aged 2 to under 12 with uncontrolled chronic spontaneous urticaria has completed, with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• DUPIXENT (DUPILUMAB)

Snippet

Sponsor: Sanofi | Conditions: Chronic Spontaneous Urticaria | Phase 3 | Status: COMPLETED | Results posted: 2025-11-19